PTEN status in advanced colorectal cancer treated with cetuximab.
Br J Cancer
; 102(1): 162-4, 2010 Jan 05.
Article
in En
| MEDLINE
| ID: mdl-19953097
ABSTRACT
BACKGROUND:
Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway.METHODS:
PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n=43) and on metastatic (n=24) sites in CRC patients treated with cetuximab.RESULTS:
The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; P<0.05), PFS (0.8 vs 8.2 months; P<0.001) and OS (2.9 vs 14.2 months; P<0.001).CONCLUSION:
A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
/
Adenocarcinoma
/
Antineoplastic Combined Chemotherapy Protocols
/
Protein Kinase Inhibitors
/
PTEN Phosphohydrolase
/
ErbB Receptors
/
Antibodies, Monoclonal
/
Neoplasm Proteins
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Br J Cancer
Year:
2010
Type:
Article
Affiliation country:
Italy